Qynapse To Present Clinical Results Of QyScore For Alzheimer’s Disease And Multiple Sclerosis At The 7th Congress Of The European Academy Of Neurology

By AIT News Desk On Jun 15, 2021

QYNAPSE Inc., a medical technology company commercializing the most advanced artificial intelligence neuroimaging platform, announced it will present clinical data on QyScore^® for Alzheimer’s disease and multiple sclerosis at the 7^th Congress of the European Academy of Neurology (EAN), which is being held virtually on June 19 – 22, 2021.

The QyScore^® platform, which is both FDA-cleared and CE-marked, provides automated quantification of a broad portfolio of neurodegenerative and neuroinflammatory markers and advanced visualization capabilities that are accessible by physicians. QyScore^® integrates an automated comparison of patient results with a large normative dataset of healthy controls, supporting faster clinical decisions, timely diagnosis and precise monitoring of Alzheimer’s disease, multiple sclerosis, Parkinson’s disease and other neurological disorders.

95 Percent of Retail Leaders Prioritize AI, but Only 40 Percent Feel Ready Due to Data Gaps

Nov 21, 2024

Baffle Announces Vector Database Protection to Enhance Data Security for GenAI Applications

Nov 21, 2024

H2O.ai Generative and Predictive AI Now Validated on the Dell AI Factory with NVIDIA

Nov 21, 2024

Prev Next 1 of 40,404

At the EAN Congress, Enrica Cavedo, PhD, Scientific Lead at Qynapse, will give an ePresentation titled, “Diagnostic Accuracy of QyScore^® MRI Markers in the Clinical Spectrum of Alzheimer’s Disease” on June 20, 2021, at 6:05 a.m. ET / 12:05 CEST. Additionally, Philippe Tran, R&D Scientist at Qynapse, will give an ePoster titled, “Brain Volumes Alterations in Multiple Sclerosis Patients: Comparison to QyScore^® Normative Data” on June 20, 2021, at 1:30 p.m. ET / 19:30 CEST.

“We are pleased to present new data on QyScore^® at the EAN Congress, which are showing its clinical value for the diagnosis and assessment of disease progression for multiple sclerosis, mild cognitive impairment and Alzheimer’s disease patients,” said Olivier Courrèges, CEO of Qynapse. “For Alzheimer’s disease, in light of the recent approval by the FDA of ADUHELM (Aducanumab), we are excited to work on future developments of our neuroimaging solution, to support the treatment initiation and the monitoring of its efficacy and safety. We look forward to sharing and discussing our latest advances with experts in the field throughout the EAN event.”